Claims

1. A pharmaceutical composition free of gastric coating comprising anagrelide HCl,a non-pH dependent polymer and a pharmaceutically acceptable water soluble acid, wherein the non-pH dependent polymer is selected from the group of polyacrylacids, cellulose derivatives or polyacrylamids, preferably it is Carbopol™ and wherein the amount of the non pH dependent polymer is 1.5 to 2.5 fold of anagrelide (w/w).

2. A pharmaceutical composition according to claim 1 wherein the anagrelide HCl is in the form of particles wherein at least 90% of said particles are smaller than 10 μm in diameter.

3. A pharmaceutical composition according to claim 1 or 2 comprising anagrelide HCl in an amount between 0.5 and 5 mg, preferably between 1 and 3.5 mg, preferably between 2 and 3 mg, preferably in an amount of ~~about~~ 2.3 mg.

~~4. A pharmaceutical composition according to any one of claims 1 to 3 wherein the amount of the non pH dependent polymer is about 1.5 to 2.5 fold of the pharmaceutically active agent (w/w).~~

~~5. A pharmaceutical composition according to any one of claims 1 to 4 wherein the non-pH dependent polymer is selected from the group polyacrylacids, cellulose derivatives or polyacrylamids, preferably it is Polyacrylacid 971P.~~

~~6.~~4. A pharmaceutical composition according to any one of claims 1 to ~~5~~3 wherein polyacrylacid is present in an amount between 1 and 10 mg, preferably between 2.5 and 5 mg, preferably between 3 and 4 mg.

~~7.~~5. A pharmaceutical composition according to any one of claims 1 to ~~6~~4 wherein the pharmaceutically acceptable water soluble acid is selected from the group of adipic acid, ascorbic acid, citric acid, fumaric acid, malic acid, succinic acid, tartaric acid or a mixture thereof.

~~8.~~6. A pharmaceutical composition according to any one of claims 1 to ~~7~~5 wherein the water soluble acid is present in an amount between 5 and 40 mg, preferably between 10 and 20 mg, preferably between 15 and 19 mg.

9.7. A pharmaceutical composition according to any one of claims 1 to 86 wherein anagrelide has a mean particle size of about 5 μm.

10.8. A pharmaceutical composition according to any one of claims 1 to 97 comprising microcristalline cellulose.

11.9. A pharmaceutical composition according to any one of claims 1 to 108 wherein microcristalline cellulose is present in an amount between 10 and 150 mg, preferably between 25 and 100 mg, preferably between 70 and 80 mg.

12.10. A pharmaceutical composition according to any one of claims 1 to 119 having anin-vitro release of at least 45% after 8 hours

13.11. A pharmaceutical composition according to any one of claims 1 to 1210 comprising anagrelide HCl, polyacrylacid, citric acid, microcristalline cellulose and magnesium stearate.

14.12. A pharmaceutical composition according to any one of claims 1 to 1311 which is in the form of a tablet.

15.13. Use of a pharmaceutical composition according to any one of claims 1 to 1412 for the preparation of a medicament for the treatment of essential thrombocythemia.